Consumer wearables have made the old boundary between "wellness gadget" and "medical tool" harder to see. A Nature Biomedical Engineering Comment published on 23 June 2026 argues that the FDA's 2026 General Wellness guidance does not fully settle what this shift means for validation, safety, regulatory definitions and healthcare integration. The issue is not whether a smartwatch can be useful; it is whether users understand when a clinical-style number is wellness information rather than a clinically validated measurement. This article explains the guidance and the critique; it is not medical advice, and nothing here should be used to interpret a reading or make a health decision.

What the FDA actually changed

The FDA's January 2026 guidance keeps the same basic policy: low-risk products intended only for general wellness use are generally outside active medical-device enforcement. The important update is how the guidance treats certain noninvasive physiological trackers. Legal analyses of the guidance note that products estimating or outputting parameters such as blood pressure, oxygen saturation, blood glucose or heart-rate variability may still qualify as general wellness products if they stay within wellness use, avoid disease diagnosis or treatment claims, do not label outputs as pathological or diagnostic, and do not provide ongoing alerts or recommendations for medical management.

That is a notable softening from the FDA's 2025 posture toward some blood-pressure features. In July 2025, the agency warned WHOOP that its Blood Pressure Insights feature was being marketed without required clearance or approval, and in September 2025 the FDA separately warned consumers and healthcare providers not to use unauthorised devices that claim to measure or estimate blood pressure. The 2026 guidance does not make every blood-pressure-style feature acceptable; it narrows the path for when a noninvasive, wellness-framed output may remain outside medical-device treatment.

That path was then demonstrated in real time. On 23 June 2026, the FDA closed its WHOOP warning letter, stating that after the company modified the Blood Pressure Insights feature and its labelling — consistent with the 2026 General Wellness guidance — it did not intend to enforce device requirements on the modified feature. The agency was explicit that the closure applied specifically to the modified feature, not to blood-pressure features in general. In other words, the line moved, but it did not disappear: WHOOP reached the wellness side of it by changing the product, not by the rules simply waving it through.

What the researchers say is unaddressed

The critique — by Stephanie A. Sullivan, Jessilyn P. Dunn and colleagues — is a Comment article rather than a call to scrap the guidance, and it focuses on four areas the authors argue the guidance does not resolve. The first is validation standards: if a wellness device can display a clinical-type physiological number, how accurate does that number have to be, and against what benchmark? The second is safety risks: what happens when people act on readings that were never held to a medical-device evidence bar. The third is definitional coherence — the difficulty of keeping a clean line between "wellness" and "medical" when the same measurement can sit on either side depending on how it is framed. The fourth is healthcare integration: how these consumer-generated readings interact with the clinical system, including the clinicians who may end up fielding them.

From the public abstract and article metadata, what is clear is the shape of the authors' concern — that the guidance expands what wellness devices may display faster than it settles how trustworthy those displays must be. In the interest of transparency, Nature also discloses relevant author interests, including Jessilyn Dunn's advisory and consulting roles with Google Consumer Health, Samsung Research America and Jones Day, and Karnika Singh's employment at IQVIA. Those do not invalidate the critique, but they are worth knowing.

Why the guidance still has a case

It is worth being fair to the guidance, because it is not without merit and industry has largely welcomed it. Legal and regulatory analysts have described the 2026 update as clearer and more contemporary than the 2019 version, and as broadly favourable to innovation in wearables and sensor-based products. At the same time, even supportive analyses have noted that it opens as many questions as it settles — for instance, whether a sensor output can imply a medical condition, and how companies apply the FDA's nuanced criteria in practice. The guidance is also nonbinding, which means much will depend on how the FDA actually enforces it over time, as the WHOOP closure shows it now intends to. So the Nature critique is one considered expert perspective in a genuinely unsettled area, not the last word.

What this means if you own a wearable

The practical takeaway for consumers is about expectations, not action. The regulatory line has moved so that more devices can show you clinical-style numbers under a "general wellness" label — which means those readings are not necessarily held to the same validation and evidence standards as an FDA-cleared medical device. A wellness reading is best treated as wellness information: useful for spotting trends and prompting you to pay attention, but not a diagnosis and not a substitute for proper medical measurement.

Helpfully, the guidance itself permits wellness products to nudge you to consult a healthcare professional when a reading falls outside a normal range, and that is exactly the right instinct. If a device flags something that worries you, or if you are thinking about acting on any reading from a wearable, the appropriate next step is a qualified healthcare professional who can use validated equipment and your full context — not the wristband, and certainly not an article like this one. Treat your device as a helpful companion for healthy habits, and leave the diagnosis to people trained and equipped to make it.

Key Takeaways

  • A Nature Biomedical Engineering Comment published on 23 June 2026 argues the FDA's 2026 wellness-device guidance leaves key implications unaddressed, across validation standards, safety risks, definitional coherence and healthcare integration.

  • The FDA's 2026 General Wellness guidance (January 2026, superseding the 2019 version) lets certain noninvasive sensors that estimate parameters such as blood pressure, oxygen saturation, blood glucose and heart-rate variability count as "general wellness," provided they stay within strict wellness-use conditions — a softening of the agency's 2025 posture, which included a 14 July 2025 warning letter to WHOOP.

  • On 23 June 2026 the FDA closed that WHOOP warning letter after the company modified its Blood Pressure Insights feature to fit the new guidance — evidence that the line moved but still has conditions, and applied narrowly to the modified feature.

  • For consumers, the practical point is expectations, not action: wellness-device readings are not necessarily held to medical-device validation standards, so treat them as wellness information and consult a qualified healthcare professional for any health concern or before acting on a reading. This article is not medical advice.